← Pipeline|OBS-1037

OBS-1037

Preclinical
Source: Trial-derived·Trials: 1
Modality
Fusion Protein
MOA
USP1i
Target
MDM2
Pathway
Notch
MDSFSGS
Development Pipeline
Preclinical
Mar 2017
Mar 2028
PreclinicalCurrent
NCT07607678
2,111 pts·FSGS
2017-032028-03·Active
2,111 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-202.0y awayInterim· FSGS
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Preclinical
Active
Catalysts
Interim
2028-03-20 · 2.0y away
FSGS
Active|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT07607678PreclinicalFSGSActive2111Safety
Competitors (10)
DrugCompanyPhaseTargetMOA
LLY-6079Eli LillyPhase 2MDM2PRMT5i
LLY-3251Eli LillyPhase 2MDM2BiTE
SNY-2934SanofiPhase 3KRASG12DUSP1i
GSK-7987GSKPhase 3MDM2PD-1i
AMG-2752AmgenPreclinicalMDM2WRNi
AMG-9052AmgenPhase 2/3CDK2USP1i
REG-3155RegeneronPhase 1/2MDM2PI3Ki
DatozumabRegeneronPhase 1B7-H3USP1i
GMA-729GenmabPhase 2BCL-2USP1i
SRP-1135SareptaPhase 2/3MDM2PD-L1i